Category Archives: People

Vampire Surf Club Made Its Runway Debut at Miami Swim Week with a Luxury Case for Covering Up

The Venice, California surf and swimwear label, founded by designer Nicola Morgan, brought UPF50+ sun protection in Italian ECONYL® regenerated nylon and Japanese limestone neoprene to the runway at RISE by Paraiso Miami Swim Week, presenting its Spring/Summer 2026 collection and a first look at Fall 2026. Miami, FL, June 18, 2026 (GLOBE NEWSWIRE) — […]

Flora Materials’ Shoreline Flooring Collection Earns Best of NeoCon 2026 Sustainability Award

Award recognizes bio-based flooring tile made with oyster shell byproducts for advancing sustainable material innovation in commercial interiors CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — Flora Materials, a Colorado-based biomaterials company, has received the Best of NeoCon 2026 Sustainability Award, one of the industry’s top recognitions for environmentally responsible interior product design, for its Shoreline […]

Teva Releases Q2 2026 Aide Memoire

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website. Q2 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to […]

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, […]

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and […]

Autonomix Announces Reverse Stock Split

THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect […]

Teads Launches CTV Ensemble for Unified Omnichannel Orchestration

Comprehensive suite provides a single global access point for high-attention formats and measurable results – from brand storytelling to bottom-line performance. The launch highlights the general availability of Teads CTV Performance, bringing AI-driven, lower-funnel outcomes directly to the living room. NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform, […]

L’Oréal to acquire a majority stake in Innovist, a leading digital-first Indian personal care house of brands

Strategic expansion in India: This investment reinforces L’Oréal’s commitment to India and accelerates its strategy to scale and lead in one of the world’s fastest-growing beauty markets. Highly complementary brand fit: Innovist’s digital-first brands naturally complement L’Oréal’s existing portfolio, bringing high-performing science-led products specifically tailored for Indian consumers Operational continuity: Agreement retains the expertise of Innovist’s founding team […]

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

        Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— […]

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases Denali was awarded Priority Review Voucher following FDA approval of AVLAYAH™, the first FDA-approved biologic specifically designed to cross blood-brain barrier SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) […]